Skip to main content
Premium Trial:

Request an Annual Quote

French Firm Synt:em Gains New Financing From Venture Backers

Premium

NÎMES--Synt:em here, a drug discovery company that specializes in research tools and services for peptide synthesis and contract research for the design and synthesis of new therapeutic molecules, has completed a new round of financing that brought in approximately $3.4 million. The firm is now supported by two venture companies, Apax Partners and Banexi Ventures, and is capitalized with more than $4.25 million.

In addition, Synt:em has received an innovation grant of more than $1 million from the French government. According to the company, the new funds will be used to develop its Pep:Trans technology that allows therapeutic molecules to be delivered to intracellular targets more efficiently. Pep:Trans utilizes Synt:em's In Silico Screening technology platform, based on chemical synthesis and molecular modeling.

Filed under

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.